Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
204
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations

David M. Cordas dos Santosa Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;b Cancer- and Immunometabolism Research Group, Gene Center LMU, Munich, Germany;c German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttps://orcid.org/0000-0002-9198-8338View further author information
ORCID Icon,
Tanja Pauld Institute of Pathology, LMU Munich, Munich, GermanyView further author information
,
Wolfgang G. Kunze Department of Radiology, University Hospital, LMU Munich, GermanyView further author information
,
Martina Rudeliusd Institute of Pathology, LMU Munich, Munich, GermanyView further author information
&
Sebastian Theuricha Department of Medicine III, University Hospital, LMU Munich, Munich, Germany;b Cancer- and Immunometabolism Research Group, Gene Center LMU, Munich, Germany;c German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, GermanyCorrespondence[email protected]
View further author information
Pages 2706-2710 | Received 04 Mar 2022, Accepted 24 Jun 2022, Published online: 06 Jul 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Author contributions

Conceptualization: DMCDS, ST Investigation: DMCDS, TP, MR, ST Formal Analysis and Visualization: DMCDS, WGK, TP Writing Original Draft: DMCDS, ST Writing Review and Editing: DMCDS, WGK, TP, MR, ST.

All authors read and approved the final manuscript.

Disclosure statement

DMCDS, TP, MR and WGK do not have any COIs to disclose. ST received honoraria from and consulted for Amgen, BMS/Celgene, GSK, Janssen, Pfizer, Sanofi and Takeda.

Additional information

Funding

DMCDS: This work was partly supported by a fellowship from the School of Oncology of the German Cancer Consortium (DKTK), Munich site and funding from the Medical Faculty of Ludwig-Maximilians-University in Munich, Germany [FöFoLe, Reg.-Nr. 1089].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.